Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms AMERICAN JOURNAL OF CLINICAL PATHOLOGY Li, H., Hasserjian, R. P., Kroft, S. H., Harrington, A. M., Wheaton, S. E., Pildain, A., Ewalt, M. D., Gratzinger, D., Hosking, P., Olteanu, H. 2016; 145 (4): 538-551

Abstract

Pure erythroid leukemia (PEL) is an extremely rare entity that may, even more rarely, evolve from a preexisting chronic myeloid neoplasm (CMN); there is minimal literature regarding this latter phenomenon.We describe 14 patients with PEL that represented progression from a preexisting myelodysplastic syndrome (MDS, n?=?8) or myeloproliferative neoplasm (MPN, n?=?6), three of which manifested as erythroblastic sarcoma (EBS), a rare entity. These patients had a highly complex karyotype with prominent clonal evolution and a very aggressive clinical course.Patients with PEL from MDS showed a more rapid progression time to PEL and had lower platelet counts compared with PEL from MPN. No other significant differences were found between the two groups.These data represent the largest cohort of patients with PEL and an antecedent CMN, as well as the largest series of EBS reported to date, and underscore the unique morphologic, cytogenetic, immunophenotypic, and clinical features of this uncommon entity.

View details for DOI 10.1093/ajcp/aqw033

View details for Web of Science ID 000376947200012

View details for PubMedID 27124944